Clarification: This is NOT from the ADA Guidelines
No, the information you're asking about is from the 2024 American College of Physicians (ACP) guideline, not the American Diabetes Association (ADA) guideline. These are two distinct professional organizations with different approaches to type 2 diabetes management 1.
Key Differences Between ACP and ADA Guidelines
American College of Physicians (ACP) 2024 Recommendations:
- Strongly recommends adding SGLT-2 inhibitors or GLP-1 agonists to metformin for inadequate glycemic control, prioritizing mortality and cardiovascular outcomes 1
- Strongly recommends AGAINST adding DPP-4 inhibitors to metformin, citing lack of mortality/morbidity benefit 1
- Targets HbA1c between 7-8% for most adults and recommends deintensifying if HbA1c falls below 6.5% 1
- Emphasizes cost considerations and prioritizes medications with proven mortality benefits 1
American Diabetes Association (ADA) Approach:
- Takes a more patient-centered, individualized approach to medication selection 1
- Does NOT make strong recommendations against DPP-4 inhibitors; instead considers them as one option among several second-line agents 1
- Generally targets HbA1c <7% for most adults (more stringent than ACP) 1
- Emphasizes shared decision-making considering efficacy, hypoglycemia risk, weight effects, side effects, and cost 1
Important Clinical Implications
The ACP guideline is more prescriptive:
- It explicitly prioritizes SGLT-2 inhibitors for patients with heart failure or chronic kidney disease 1
- It explicitly prioritizes GLP-1 agonists for patients with stroke risk or weight loss goals 1
- It takes a firm stance against DPP-4 inhibitors based on lack of mortality benefit 1
The ADA guideline is more flexible:
- It allows consideration of DPP-4 inhibitors, sulfonylureas, thiazolidinediones, or other agents as second-line options 1
- It emphasizes the 2022 ADA/KDIGO consensus for patients with CKD, which strongly recommends SGLT-2 inhibitors 1
Why This Matters in Practice
When citing guidelines to justify treatment decisions, you must specify which organization's recommendations you're following. The ACP 2024 guideline represents a more evidence-based, outcomes-focused approach that prioritizes mortality and cardiovascular benefits 1. The ADA Standards of Care (updated annually, most recently 2026) provides broader treatment options with more emphasis on individualization 2, 3, 4, 5.
Both guidelines agree on metformin as first-line therapy and the importance of SGLT-2 inhibitors and GLP-1 agonists for patients with cardiovascular disease or kidney disease 1. The main divergence is in the strength of recommendations against DPP-4 inhibitors and the target HbA1c ranges.